Trial intelligence / Profile preview

CASCADES

2023-508525-27-00Phase 4Authorised

Sponsor: National Institute of Cardiology
Start: Mar 2024
Modality: Recombinant Proteins and Enzymes, Peptides, Small Molecules
Countries: 1

Overview

Phase 4, randomised, open-label trial of semaglutide, dapagliflozin and metformin in coronary arteriosclerosis and prediabetes (3 arms), sponsored by National Institute of Cardiology. Planned start Mar 2024; status: authorised.

Drugs

semaglutidedapagliflozinmetformin

Conditions

coronary arteriosclerosisprediabetes

Beyond the preview

Go deeper on 2023-508525-27-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2023-508525-27-00.